Skin Cancer & Melanoma

Latest News

ctDNA May Help to Predict Early Recurrence in Stage III Melanoma
ctDNA May Help to Predict Early Recurrence in Stage III Melanoma

April 22nd 2025

ctDNA levels may help to predict early recurrence for patients with stage III melanoma before adjuvant therapy and during follow-up.

Data from RELATIVITY-047 show consistent benefits with nivolumab/relatlimab across most patient subgroups, including those with BRAF-mutated disease.
Nivolumab/Relatlimab Shows Sustained Efficacy in Advanced Melanoma

February 15th 2025

RP1/Nivolumab Earns Priority Review in Anti–PD-1 Failed Advanced Melanoma
RP1/Nivolumab Earns Priority Review in Anti–PD-1 Failed Advanced Melanoma

January 21st 2025

Investigators of the phase 3 C-POST trial will continue to follow up with patients and assess the key secondary end point of overall survival.
Adjuvant Cemiplimab Boosts DFS in Cutaneous Squamous Cell Carcinoma

January 13th 2025

Cosibelimab has been approved by the FDA as a treatment for patients with cutaneous squamous cell carcinoma.
FDA Approves Cosibelimab in Cutaneous Squamous Cell Carcinoma

December 13th 2024

More News